Chronic Rhinosinusitis Without Nasal Polyps Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Lyra Therapeutics, Insmed, Sanofi

DelveInsight Business Research LLP

DelveInsight’s “Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology and the chronic rhinosinusitis without nasal polyps market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Chronic Rhinosinusitis Without Nasal Polyps Key Highlights 

• Key Companies working in the Chronic Rhinosinusitis Without Nasal Polyps  market include Lyra Therapeutics, Insmed, Sanofi, Regeneron Pharmaceuticals, and many others.

• Key Therapies included in the Chronic Rhinosinusitis Without Nasal Polyps  market include XHANCE (fluticasone propionate), LYR-210, and many others 

Chronic Rhinosinusitis Without Nasal Polyps Overview

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is a prevalent and chronic medical condition characterized by inflammation and swelling of the nasal passages and paranasal sinuses, but notably, it does not involve the presence of nasal polyps. Individuals with chronic rhinosinusitis without nasal polyps often experience symptoms such as nasal congestion, difficulty breathing through the nose, facial pain or pressure, reduced sense of smell (hyposmia), and a persistent discharge from the nose. These symptoms typically last more than 12 weeks, making it a chronic condition requiring proper management.

Chronic Rhinosinusitis Without Nasal Polyps Epidemiology Insights

• In 2022, among the 7MM, the US recorded the highest number of prevalent cases of Chronic Rhinosinusitis (CRS), with approximately 31 million cases. Across all the 7MM countries, the total number of prevalent CRS cases was approximately 71 million, and these cases are projected to increase by 2032.

• In 2022, there were an estimated 9 million diagnosed cases of CRS out of a total of 31 million prevalent cases in EU4 and the UK.

• DelveInsight’s analysis indicates that approximately 81% of the total diagnosed cases of CRS in the 7MM were diagnosed as chronic rhinosinusitis without nasal polyps accounting for about 17 million cases in the 7MM, among which the US accounted for 51% of the cases.

Click here to learn more about the Chronic Rhinosinusitis Without Nasal Polyps Market Landscape

The Report Covers the Chronic Rhinosinusitis Without Nasal Polyps Epidemiology Segmented by:

• Chronic Rhinosinusitis Without Nasal polyps Prevalent cases 

• Chronic Rhinosinusitis Without Nasal Polyps Incident cases 

• Chronic Rhinosinusitis Without Nasal Polyps Treatment cases 

• Chronic Rhinosinusitis Without Nasal Polyps Diagnosed cases 

Chronic Rhinosinusitis Without Nasal Polyps Market Outlook 

Chronic Rhinosinusitis Without Nasal Polyps has a diverse treatment classification associated with the disease landscape. The primary goal of treatment for chronic rhinosinusitis without nasal polyps is to reduce inflammation, control symptoms, and improve the patient’s quality of life. Antibiotics and corticosteroids are major revenue generators in the current treatment landscape. The use of antibiotics and corticosteroids (intranasal and oral) is guided by clinical practice guidelines, which provide evidence-based recommendations to healthcare professionals to manage CRSsNP.

Key Companies Working in the Chronic Rhinosinusitis Without Nasal Polyps Market 

• Lyra Therapeutics

• Insmed

• Sanofi

• Regeneron Pharmaceuticals

And many others 

Chronic Rhinosinusitis Without Nasal PolypsTherapies Covered and Analyzed in the Report

• XHANCE (fluticasone propionate)

• LYR-210

And many others 

Learn more about the Key Companies and Emerging Therapies in the Chronic Rhinosinusitis Without Nasal Polyps Market

Table of Contents 

1.  Key Insights 

2.  Chronic Rhinosinusitis Without Nasal Polyps  Introduction 

3.  Executive Summary of Chronic Rhinosinusitis Without Nasal Polyps          

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Chronic Rhinosinusitis Without Nasal Polyps  Emerging Therapies

7.  Chronic Rhinosinusitis Without Nasal Polyps  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Chronic Rhinosinusitis Without Nasal Polyps Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services